VRTX · Company research
8 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Vertex expects to report results from its Phase 2 study of inaxaplin (VX-147) for APOL1-mediated kidney disease with moderate proteinuria and with Type 2 diabetes in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex expects to report results from its Phase 1/2 study of VX-828 for Cystic fibrosis in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Updated program timelines for zimislecel and VX-017 later in 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Vertex (Zimislecel (VX-880) / VX-017 for Type 1 diabetes): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex presents data on ALYFTREK / TRIKAFTA / CF pipeline for Cystic fibrosis at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex expects to report results from its Phase 2/3 study of inaxaplin (VX-147) for APOL1-mediated kidney disease in Q4 2026 (Oct–Dec) (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Suzetrigine DPN Phase 3 enrollment completion by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Vertex (Suzetrigine (JOURNAVX) for Diabetic peripheral neuropathy): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is due to decide by Nov 30, 2026 whether to approve Vertex’s povetacicept (dual BAFF/APRIL inhibitor) for IgA nephropathy (accelerated approval). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex expects to report results from its Phase 2/3 study of Inaxaplin (VX-147) for APOL1-mediated kidney disease in the first half of 2027 (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex acquisition of Crinetics expected to close in Q3 2026, in Q3 2026 (Jul–Sep). A company milestone for Vertex (Paltusotine (PALSONIFY) / atumelnant (Crinetics) for Acromegaly / endocrine (acquisition)): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Vertex’s CASGEVY (exagamglogene autotemcel) for Sickle cell disease and transfusion-dependent beta thalassemia, ages 2+ on Jul 1, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex presented data on CASGEVY (exagamglogene autotemcel) for Sickle cell disease and transfusion-dependent beta thalassemia at a medical meeting on Jun 11, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex presented data on ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for Cystic fibrosis at a medical meeting on Jun 5, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
FDA accepts povetacicept BLA in IgAN; PDUFA target date November 30, 2026, on Jun 1, 2026. A company milestone for Vertex (Povetacicept for IgA nephropathy): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex reported results from its Phase 3 study of Povetacicept for IgA nephropathy on Mar 9, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex reported results from its Phase 3 study of Journavx (suzetrigine) for Acute pain on Jan 30, 2024. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Vertex’s Casgevy (exa-cel) for Sickle cell disease on Dec 8, 2023. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to VRTX.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.